CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Apr. 02, 2022
Cash Flows from Operating Activities:
Net income	$ 117,558	$ 115,401	$ 43,375
Non-cash items:
Depreciation and amortization	97,215	93,307	97,747
Impairment of assets	10,419	607	7,953
Share-based compensation expense	28,332	25,583	24,359
Gains on divestiture and sale of assets	2,000	382	9,603
Contingent consideration	0	(504)	10,461
Amortization of fair value inventory step-up	3,347	0	0
Deferred tax benefit	(11,039)	4,783	5,013
Amortization of deferred financing costs	3,175	1,970	3,404
Provision (benefit) for losses on inventory	9,312	664	(861)
Other non-cash operating activities	133	6,126	5,592
Change in operating assets and liabilities:
Change in accounts receivable	(24,193)	(24,421)	(34,974)
Change in inventories	(60,061)	30,754	24,307
Change in prepaid income taxes	(983)	1,688	2,870
Change in other assets and other liabilities	(34,046)	(22,334)	(15,022)
Change in accounts payable and accrued expenses	44,582	39,816	7,642
Net cash provided by operating activities	181,751	273,058	172,263
Cash Flows from Investing Activities:
Capital expenditures	(66,296)	(110,191)	(96,509)
Proceeds from divestiture and sale of assets	1,500	850	10,642
Proceeds from sale of property, plant and equipment	1,810	1,608	2,022
Payments to Acquire Businesses, Net of Cash Acquired	243,852	2,850	2,500
Payments to Acquire Other Investments	(15,551)	(33,205)	0
Net cash used in investing activities	(322,389)	(143,788)	(86,345)
Cash Flows from Financing Activities:
Term loan borrowings	0	280,000	0
Term loan redemption	0	(280,000)	0
Repayment of term loan borrowings	(12,250)	(9,625)	(17,500)
Proceeds from revolving facility	110,000	50,000	0
Payments on revolving facility	(60,000)	(50,000)	0
Debt issuance costs	0	(1,118)	0
Contingent consideration payments	(849)	(21,593)	(4,791)
Proceeds from employee stock purchase plan	5,604	4,378	4,209
Proceeds from exercise of stock options	1,610	2,638	2,338
Payment, Tax Withholding, Share-Based Payment Arrangement	(5,885)	0	0
Share repurchases	0	(75,000)	0
Other financing activities	(73)	(44)	(5)
Net cash provided by (used in) financing activities	38,157	(100,364)	(15,749)
Effect of exchange rates on cash and cash equivalents	(3,185)	(3,936)	(2,978)
Net Change in Cash and Cash Equivalents	(105,666)	24,970	67,191
Cash and Cash Equivalents at Beginning of Year	284,466	259,496	192,305
Cash and Cash Equivalents at End of Year	178,800	284,466	259,496
Supplemental Disclosures of Cash Flow Information:
Interest paid	20,901	13,587	6,187
Income taxes paid	52,706	17,967	24,298
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 28,781	$ 81,136	$ 51,800